Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept

Journal of Rheumatology

Volumn 40, Issue 2, 2013, Pages 192-200

  Solari, Nicoletta ^a   Palmisani, Elena ^a   Consolaro, Alessandro ^a   Pistorio, Angela ^a   Viola, Stefania ^a   Buoncompagni, Antonella ^a   Gattorno, Marco ^a   Picco, Paolo ^a   Ruperto, Nicolino ^a   Malattia, Clara ^b   Martini, Alberto ^b   Ravelli, Angelo ^a,b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Etanercept; Juvenile idiopathic arthritis; Outcome predictors; Remission; Treatment response

Indexed keywords

ETANERCEPT;

ADOLESCENT; ANGIONEUROTIC EDEMA; ARTICLE; BRONCHOPNEUMONIA; CHICKENPOX; CHILD; DISEASE ACTIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; ONSET AGE; PAPILLEDEMA; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; THROMBOCYTOPENIA; TUBERCULOSIS; URTICARIA; WRIST;

ADOLESCENT; AGE FACTORS; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; MALE; PROPORTIONAL HAZARDS MODELS; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WRIST;

EID: 84873582918     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120842     Document Type: Article

References (43)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
2. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671-84.
3. Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: Treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009;11:216.
4. Ruperto N, Martini A. Emerging drugs to treat juvenile idiopathic arthritis. Expert Opin Emerg Drugs 2011;16:493-505.
5. Wallace CA, Ruperto N, Giannini EH. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4.
6. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res 2011;63:929-36.
7. Ravelli A, Martini A. Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 2006;24 Suppl 43:S105-10.
8. Magni-Manzoni S, Ruperto N, Pistorio A, Sala E, Solari N, Palmisani E, et al. Development and validation of a preliminary definition of minimal disease activity in juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1120-7.
9. Martini A, Lovell DJ. Juvenile idiopathic arthritis: State of the art and future perspectives. Ann Rheum Dis 2010;69:1260-3.
10. Ruperto N, Giannini EH, Pistorio A, Brunner HI, Martini A, Lovell DJ. Is it time to move to active comparator trials in juvenile idiopathic arthritis? A review of current study designs. Arthritis Rheum 2010;62:3131-9.
11. Wallace CA, Giannini EH, Spalding SJ, Hashkes PJ, O'Neil KM, Zeft AS, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum 2012;64:2012-21.
12. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
13. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48:1093-101.
14. Horneff G, Schmeling H, Biedermann T, Foeldvari I, Ganser G, Girschick HJ, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44.
15. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2009;60:2794-804.
16. Halbig M, Horneff G. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int 2009;30:229-38.
17. Prince FH, Geerdink LM, Borsboom GJ, Twilt M, van Rossum MA, Hoppenreijs EP, et al. Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Ann Rheum Dis 2010;69:138-42.
18. Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2010;62:3259-64.
19. Billiau AD, Loop M, Le PQ, Berthet F, Philippet P, Kasran A, et al. Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. Rheumatology 2010;49:1550-8.
20. Nielsen S, Ruperto N, Gerloni V, Simonini G, Cortis E, Lepore L, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26:688-92.
21. Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology 2011;50:214-21.
22. Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA 2011;306:2340-7.
23. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton 2001. J Rheumatol 2004;31:390-2.
24. Ravelli A, Varnier GC, Oliveira S, Castell E, Arguedas O, Magnani A, et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 2011;63:267-75.
25. Clayton D, Hills M. Statistical models in epidemiology. New York: Oxford University Press; 1993.
26. Magni-Manzoni S, Rossi F, Pistorio A, Temporini F, Viola S, Beluffi G, et al. Prognostic factors for radiographic progression, radiographic damage, and disability in juvenile idiopathic arthritis. Arthritis Rheum 2003;48:3509-17.
27. Cassone R, Falcone A, Rossi F, Magni-Manzoni S, Felici E, Buoncompagni A, et al. Unilateral destructive wrist synovitis in juvenile idiopathic arthritis. Clin Exp Rheumatol 2004;22:637-42.
28. Malattia C, Damasio MB, Magnaguagno F, Pistorio A, Valle M, Martinoli C, et al. Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1764-72.
29. Al-Matar MJ, Petty RE, Tucker LB, Malleson PN, Schroeder ML, Cabral DA. The early pattern of joint involvement predicts disease progression in children with oligoarticular (pauciarticular) juvenile rheumatoid arthritis. Arthritis Rheum 2002;46:2708-15.
30. Felici E, Novarini C, Magni-Manzoni S, Pistorio A, Magnani A, Bozzola E, et al. Course of joint disease in patients with antinuclear antibody-positive juvenile idiopathic arthritis. J Rheumatol 2005;32:1805-10.
31. Oen K. Long-term outcomes and predictors of outcomes for patients with juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 2002;16:347-60.
32. Ravelli A, Viola S, Migliavacca D, Ruperto N, Pistorio A, Martini A, et al. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 1999;135:316-20.
33. Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, et al. Pediatric Rheumatology International Trials Organization (PRINTO). Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: Analysis of the PRINTO methotrexate trial. Ann Rheum Dis 2010;69:1479-83.
34. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): Preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25.
35. Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J Rheumatol 2005;32:935-42.
36. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, et al. Long term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis; the Dutch national register. Ann Rheum Dis 2009;68:635-41.
37. Southwood TR, Foster HE, Davidson JE, Hyrich KL, Cotter CB, Wedderburn LR, et al. British Society for Adolescent and Paediatric Rheumatology Biologics and New Drugs Register. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 2011; 50:189-95.
38. Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P. Drug survival of the first and second course of antitumour necrosis factor agents in juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:552-7.
39. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86.
40. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:929-31.
41. Tzaribachev N, Fritz J, Horger M. Silent arthritis in JIA children with clinically inactive disease detected by MRI. Ann Rheum Dis 2011;70 Suppl 3:90.
42. Rebollo-Polo M, Koujok K, Weisser C, Jurencak R, Bruns A, Roth J, et al. Ultrasound findings on patients with juvenile idiopathic arthritis in clinical remission. Arthritis Care Res 2011;63:1013-9.
43. Magni-Manzoni S, Scirè CA, Ravelli A, Klersy C, Rossi S, Muratore V, et al. Ultrasound-detected synovial abnormalities are frequent in clinically inactive juvenile idiopathic arthritis, but do not predict a flare of synovitis. Ann Rheum Dis 2012 June 26 [E-pub ahead of print].